Phone :+91-(522)-2772450/2772550 Search

Research Interests


Interactions between host and the parasite during infection define the systemic localization and continuous persistence of the pathogen by regulating the host-protective signaling pathways and communications between the cells of the immune system. During the course of evolution, pathogens have developed survival strategies like manipulation of the host immune system to overcome the lethal pathogen-clearing responses. The research from our lab aims to define the survival tactics of Leishmania donovani, a protozoan parasite that infects macrophages and the causative agent of visceral leishmaniasis, a lethal infectious disease affecting millions worldwide. We study the interaction of Leishmania with immune cells like macrophages, dendritic cells and T cells and the fate of these interactions on modulation of various intracellular signaling cascades that ultimately affect immune response/infection progression.


Our lab is actively involved in the anti-leishmanial drug discovery programme of CSIR-CDRI where we use luciferase expressing transgenic L. donovani parasite for high-throughput anti-leishmanial screening of several synthetic compounds/natural products.

Recent Publications


  • Leishmania donovani Exploits Tollip, a multitasking protein, to impair TLR/IL-1R signaling for its survival in the host. J Immunol (2018).Parmar N, Chandrakar P, Vishwakarma P, Singh K , Mitra K, Kar S. [Epub ahead of print] (Impact Factor- 4.92)
  • Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.Vishwakarma P, Parmar N, Chandrakar P, Sharma T, Kathuria M, Agnihotri PK, Siddiqi MI, Mitra K, Kar S.. Cell Mol Life Sci. (2017) 75(3):563-588 (Impact Factor – 6.7)
  • Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis.Roy S, Dutta D, Satyavarapu EM, Yadav PK, Mandal C, Kar S, Mandal C. Sci Rep. (2017) 23;7(1):4141(Impact Factor – 4.2)
  • Antileishmanial Activity of Pyrazolopyridine Derivatives and Their Potential as an Adjunct Therapy with Miltefosine Anand D, Yadav PK, Patel OP, Parmar N, Maurya RK, Vishwakarma P, Raju KS, Taneja I, Wahajuddin M, Kar S*, Yadav PP*. . J Med Chem. (2017);60(3):1041-1059. (*Corresponding author) (Impact Factor – 6.2)
  • 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis. Vishwakarma P, Parmar N, Yadav PK, Chandrakar P, Kar S.. J Mol Med (Berl). (2016) 94(6):695-710 (Impact Factor – 4.7)
  • Protection against filarial infection by 45-49 kDa molecules of Brugia malayi via IFN-γ-mediated iNOS induction. Vaccine (2015) 33:527-34. Verma SK, Joseph SK, Verma R, Kushwaha V, Parmar N, Yadav PK, Thota JR, Kar S, Murthy PK. (Impact Factor – 3.38)
  • Combination of liposomal CpG Oligodeoxynucleotide 2006 and Miltefosine induces Strong Cell-mediated Immunity during experimental visceral leishmaniasis. Plos One (2014) 14;9(4):e94596. Shivahare, R.,Vishwakarma, P., Parmar N, Yadav PK, Haq, W.,Srivastava M, Gupta, S, and Kar, S. (Impact Factor – 3.7)
  • Successful therapy of visceral leishmaniasis with curdlan involves T-helper 17 cytokines. J infect Dis. 2013 15; 207(6):1016-25 Ghosh K, Sharma G, Saha A, Kar S, Das PK, Ukil A. (Impact Factor – 5.99)
  • Leishmania donovani exploits host deubiquitinating enzyme A20, a negative regulator of TLR signaling, to subvert host immune response. J. Immunol (2012) 189, 924-934 *Srivastav, S.,1 Kar, S1, Chande, A G., Mukhopadhyaya R and Das, P.K. (1Equal contribution). (Impact Factor – 5.745)